Nonetheless, while anti-angiogenic therapies are effective in many cancers, their effectiveness is likely modulated by obesity-associated signaling, such as through the leptin signaling axis. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.